• Vaccine Ontology ID: VO_0004342
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Human
• env gene engineering:
  • Type: Recombinant vector construction
  • Description: This recombinant vector vaccine expressed env from HIV-1 (Barouch et al., 2012).
  • Detailed Gene Information: Click Here.
• Gag from HIV 1 gene engineering:
  • Type: DNA vaccine construction
  • Description: This recombinant vector vaccine expressed gag from HIV-1 (Barouch et al., 2012).
  • Detailed Gene Information: Click Here.
• env from SIV gene engineering:
  • Type: Recombinant vector construction
  • Description: This recombinant vector vaccine expressed env from SIV (Barouch et al., 2012).
  • Detailed Gene Information: Click Here.
• Gag protein from SIV-mnd 2 gene engineering:
  • Type: DNA vaccine construction
  • Description: This recombinant vector vaccine expressed gag from SIV (Barouch et al., 2012).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccine Immune Response Type: VO_0000286
• Efficacy: After the high-dose vaginal SHIV-162P3 challenge, 7/8 control animals were infected. Similarly, 7/8 animals in the vaccine-only group (group V) were infected. In the microbicide-only group (group M), 4/8 animals were infected. In the combination group (group V+M), only 2/7 animals were infected. The intervention efficacy in group V+M was 67%. In summary, the data supports that vaccines and microbicides used in combination may confer protection against sexual HIV-1 transmission to women by the vaginal route (Barouch et al., 2012).